The EUTOS long-term survival (ELTS) score is superior to the Sokal score for predicting survival in chronic myeloid leukemia
Markus Pfirrmann,Richard E. Clark,Witold Prejzner,Michael Lauseker,Michele Baccarani,Susanne Saussele,François Guilhot,Sonja Heibl,Rüdiger Hehlmann,Edgar Faber,Anna G. Turkina,Gert J. Ossenkoppele,Martin Höglund,Andrey Zaritskey,Laimonas Griskevicius,Ulla Olsson-Strömberg,Hele Everaus,Perttu Koskenvesa,Boris Labar,Tomasz Sacha,Daniela Zackova,Francisco Cervantes,Adriana Colita,Irena Preložnik Zupan,Andrija Bogdanovic,Fausto Castagnetti,Joelle Guilhot,Joerg Hasford,Andreas Hochhaus,Verena S. Hoffmann +29 more
Reads0
Chats0
TLDR
The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination and the recent recommendation of the European LeukemiaNet for preferred use of the ELts score was supported with significant statistical evidence.Abstract:
Prognostic scores support clinicians in selecting risk-adjusted treatments and in comparatively assessing different results For patients with chronic-phase chronic myeloid leukemia (CML), four baseline prognostic scores are commonly used Our aim was to compare the prognostic performance of the scores and to arrive at an evidence-based score recommendation In 2949 patients not involved in any score development, higher hazard ratios and concordance indices in any comparison demonstrated the best discrimination of long-term survival with the ELTS score In a second step, of 5154 patients analyzed to investigate risk group classification differences, 23% (n = 1197) were allocated to high-risk by the Sokal score Of the 1197 Sokal high-risk patients, 56% were non-high-risk according to the ELTS score and had a significantly more favorable long-term survival prognosis than the 526 high-risk patients according to both scores The Sokal score identified too many patients as high-risk and relatively few (40%) as low-risk (versus 60% with the ELTS score) Inappropriate risk classification jeopardizes optimal treatment selection The ELTS score outperformed the Sokal score, the Euro, and the EUTOS score regarding risk group discrimination The recent recommendation of the European LeukemiaNet for preferred use of the ELTS score was supported with significant statistical evidenceread more
Citations
More filters
Journal ArticleDOI
The New ELN Recommendations for Treating CML
TL;DR: Generic imatinib is the current most cost-effective first-line therapy in the chronic phase and a change of treatment is recommended when intolerance cannot be ameliorated or molecular milestones are not reached.
Journal ArticleDOI
Additional chromosomal abnormalities at chronic myeloid leukemia diagnosis predict an increased risk of progression.
TL;DR: In the United Kingdom SPIRIT2 trial comparing imatinib 400 mg daily with dasatinib 100 mg daily, diagnostic karyotypes were available in 763 of the 814 patients recruited as discussed by the authors.
Journal ArticleDOI
Is the Sokal or EUTOS long-term survival (ELTS) score a better predictor of responses and outcomes in persons with chronic myeloid leukemia receiving tyrosine-kinase inhibitors?
TL;DR: In this paper, the European Treatment and Outcome Study for CML (EUTOS) long-term survival (ELTS) scores were used to determine whether the Sokal or ELTS scores were more accurate responses and outcome predictors.
Journal ArticleDOI
Guidelines for the treatment of chronic myeloid leukemia from the NCCN and ELN: differences and similarities
TL;DR: In this paper , the authors provide a synopsis of the differences and similarities that exist between the NCCN and ELN guidelines, and provide a treatment recommendations reported in these guidelines are the result of years of selecting and incorporating the most reliable evidence.
Journal ArticleDOI
Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network
Giorgina Specchia,Patrizia Pregno,Massimo Breccia,Fausto Castagnetti,Chiara Monagheddu,Massimiliano Bonifacio,Mario Tiribelli,Fabio Stagno,Giovanni Caocci,Bruno Martino,Luigiana Luciano,Michele Pizzuti,Antonella Gozzini,Anna Rita Scortechini,Francesco Albano,Micaela Bergamaschi,Isabella Capodanno,Andrea Patriarca,Carmen Fava,Giovanna Rege-Cambrin,Federica Sorà,Sara Galimberti,Monica Bocchia,Gianni Binotto,Giovanni Reddiconto,Paolo Ditonno,Alessandro Maggi,Grazia Sanpaolo,Maria Stella De Candia,Valentina Giai,Elisabetta Abruzzese,Maria Cristina Miggiano,Gaetano La Barba,Giuseppe Pietrantuono,Anna Guella,Luciano Levato,Olga Mulas,Fabio Saccona,Gianantonio Rosti,Pellegrino Musto,Francesco Di Raimondo,Fabrizio Pane,Michele Baccarani,Giuseppe Saglio,Giovannino Ciccone +44 more
TL;DR: The role of baseline patient characteristics and first-line treatments on overall survival and CML-related mortality in 1206 newly diagnosed CML patients, 608 treated with imatinib (IMA) and 598 with 2nd generation tyrosine kinase inhibitors (2GTKI) was analyzed by the CML Italian network as mentioned in this paper.
References
More filters
Journal ArticleDOI
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Jason P. Fine,Robert Gray +1 more
TL;DR: This article proposes methods for combining estimates of the cause-specific hazard functions under the proportional hazards formulation, but these methods do not allow the analyst to directly assess the effect of a covariate on the marginal probability function.
Journal ArticleDOI
The Statistical Analysis of Failure Time Data.
Book
Modeling Survival Data: Extending the Cox Model
TL;DR: A Cox Model-based approach was used to estimate the Survival and Hazard Functions and the results confirmed the need for further investigation into the role of natural disasters in shaping survival rates.
Journal ArticleDOI
The Statistical Analysis of Failure Time Data
TL;DR: This book complements the other references well, and merits a place on the bookshelf of anyone concerned with the analysis of lifetime data from any eld.
Journal ArticleDOI
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
Michele Baccarani,Michael W. Deininger,Gianantonio Rosti,Andreas Hochhaus,Simona Soverini,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,François Xavier Mahon,Giovanni Martinelli,Jiri Mayer,Martin C. Müller,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Charles A. Schiffer,Richard T. Silver,Bengt Simonsson,Juan Luis Steegmann,John M. Goldman,Rüdiger Hehlmann +31 more
TL;DR: Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Related Papers (5)
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Andreas Hochhaus,Michele Baccarani,Richard T. Silver,Charles A. Schiffer,Jane F. Apperley,Francisco Cervantes,Richard E. Clark,Jorge E. Cortes,Michael W. Deininger,François Guilhot,Henrik Hjorth-Hansen,Timothy P. Hughes,Jeroen Janssen,Hagop M. Kantarjian,Dong-Wook Kim,Richard A. Larson,Jeffrey H. Lipton,Francois-Xavier Mahon,Jiří Mayer,Franck E. Nicolini,Dietger Niederwieser,Fabrizio Pane,Jerald P. Radich,Delphine Rea,Johan Richter,Gianantonio Rosti,Philippe Rousselot,Giuseppe Saglio,Susanne Saußele,Simona Soverini,Juan Luis Steegmann,Anna G. Turkina,Andrey Zaritskey,Ruediger Hehlmann +33 more